NR1D1 and cancer: Accordingly, the REVERBα agonist or its overexpression ameliorated the development of experimental autoimmune encephalomyelitis (EAE) in mice, proposing it as a potential future medication against immune-related adverse events (IRAE) in checkpoint-Ab-treated patients with cancer.